Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Five-Year Survival and Median Survival Time of Nasopharyngeal Carcinoma in Hospital Universiti Sains Malaysia

  • Siti-Azrin, Ab Hamid (Unit Biostatistics and Research Methodology, School of Medical Sciences, Universiti Sains Malaysia) ;
  • Norsa'adah, Bachok (Unit Biostatistics and Research Methodology, School of Medical Sciences, Universiti Sains Malaysia) ;
  • Naing, Nyi Nyi (Unit Biostatistics and Research Methodology, School of Medical Sciences, Universiti Sains Malaysia)
  • Published : 2014.08.15
Download PDF
⟨ Previous Next ⟩

Abstract

Background: Nasopharyngeal carcinoma (NPC) is the fourth most common cancer in Malaysia. The objective of this study was to determine the five-year survival rate and median survival time of NPC patients in Hospital Universiti Sains Malaysia (USM). Methods: One hundred and thirty four NPC cases confirmed by histopathology in Hospital USM between $1^{st}$ January 1998 and $31^{st}$ December 2007 that fulfilled the inclusion and exclusion criteria were retrospectively reviewed. Survival time of NPC patients were estimated by Kaplan-Meier survival analysis. Log-rank tests were performed to compare survival of cases among presenting symptoms, WHO type, TNM classification and treatment modalities. Results: The overall five-year survival rate of NPC patients was 38.0% (95% confidence interval (CI): 29.1, 46.9). The overall median survival time of NPC patients was 31.30 months (95%CI: 23.76, 38.84). The significant factors that altered the survival rate and time were age (p=0.041), cranial nerve involvement (p=0.012), stage (p=0.002), metastases (p=0.008) and treatment (p<0.001). Conclusion: The median survival of NPC patients is significantly longer for age ${\leq}50$ years, no cranial nerve involvement, and early stage and is dependent on treatment modalities.

Keywords

References

  1. Abdullah B, Alias A, Hassan S (2009). Challenges in the management of nasopharyngeal carcinoma: a review. Malays J Med Sci, 16, 50-4.
  2. Chan AT, Leung SF, Ngan RK, et al (2005). Overall survival after concurrent cisplatin-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma. J Natl Cancer Inst, 97, 536-9. https://doi.org/10.1093/jnci/dji084
  3. Chee Ee Phua V, Loo WH, Yusof, MM, et al (2013). Treatment outcome for nasopharyngeal carcinoma in University Malaya Medical Centre from 2004-2008. Asian Pac J Cancer Prev, 14, 4567-70. https://doi.org/10.7314/APJCP.2013.14.8.4567
  4. El-Sherbieny E, Rashwan H, Lubis SH, Choi VJ (2011). Prognostic factors in patients with nasopharyngeal carcinoma treated in Hospital Kuala Lumpur. Asian Pac J Cancer Prev, 12, 1739-43.
  5. Heng DM, Wee J, Fong KW, et al (1999). Prognostic factors in 677 patients in Singapore with nondisseminated nasopharyngeal carcinoma. Cancer, 86, 1912-20. https://doi.org/10.1002/(SICI)1097-0142(19991115)86:10<1912::AID-CNCR6>3.0.CO;2-S
  6. Ji X, Xie C, Hu D, et al (2013). Survival benefit of adding chemotherapy to intensity modulated radiation in patients with locoregionally advanced nasopharyngeal carcinoma. PLoS One, 8, 56208. https://doi.org/10.1371/journal.pone.0056208
  7. Kalogera-Fountzila A, Karanikolas D, Katodritis N, et al (2006). Prognostic factors and significance of the revised 6th edition of the AJCC classification in patients with locally advanced nasopharyngeal carcinoma. Strahlenther Onkol, 182, 458-66. https://doi.org/10.1007/s00066-006-1538-4
  8. Lee AW, Sze WM, Au JS, et al (2005a). Treatment results for nasopharyngeal carcinoma in the modern era: the Hong Kong experience. Int J Radiat Oncol Biol Phys, 61, 1107-16. https://doi.org/10.1016/j.ijrobp.2004.07.702
  9. Lee AW, Yau TK, Wong DH, et al (2005b). Treatment of stage IV(A-B) nasopharyngeal carcinoma by induction-concurrent chemoradiotherapy and accelerated fractionation. Int J Radiat Oncol Biol Phys, 63, 1331-8. https://doi.org/10.1016/j.ijrobp.2005.05.061
  10. Licitra L, Bernier J, Cvitkovic E, et al (2003). Cancer of the nasopharynx. Crit Rev Oncol Hematol, 45, 199-214. https://doi.org/10.1016/S1040-8428(01)00210-4
  11. Liu MT, Hsieh CY, Chang TH, et al (2003). Prognostic factors affecting the outcome of nasopharyngeal carcinoma. Jpn J Clin Oncol, 33, 501-8. https://doi.org/10.1093/jjco/hyg092
  12. Liu MZ, Tang LL, Zong JF, et al (2008). Evaluation of sixth edition of AJCC staging system for nasopharyngeal carcinoma and proposed improvement. Int J Radiat Oncol Biol Phys, 70, 1115-23. https://doi.org/10.1016/j.ijrobp.2007.07.2353
  13. Prasad U, Rampal L (1992). Descriptive epidemiology of nasopharyngeal carcinoma in Peninsular Malaysia. Cancer Causes Control, 3, 179-82. https://doi.org/10.1007/BF00051659
  14. Phua CE, Tan BS, Yong TK, Govindasamy M (2011). Retrospective analysis of results of treatment for nasopharyngeal carcinoma in Penang General Hospital from 2001-2005. Asian Pac J Cancer Prev, 12, 3197-200.
  15. Pua KC, Khoo AS, Yap YY, et al (2008). Nasopharyngeal carcinoma database. Med J Malaysia, 63, 59-62.
  16. Teo PM, Kwan WH, Lee WY, Leung SF, Johnson P J (1996). Prognosticators determining survival subsequent to distant metastasis from nasopharyngeal carcinoma. Cancer, 77, 2423-31. https://doi.org/10.1002/(SICI)1097-0142(19960615)77:12<2423::AID-CNCR2>3.0.CO;2-N
  17. Tiong TS, Selva KS (2005). Clinical presentation of nasopharyngeal carcinoma in Sarawak Malaysia. Med J Malaysia, 60, 624-8.
  18. Xie SH, Yu IT, Tse LA, Mang OW, Yue L (2013). Sex difference in the incidence of nasopharyngeal carcinoma in Hong Kong 1983-2008: suggestion of a potential protective role of oestrogen. Eur J Cancer, 49, 150-5. https://doi.org/10.1016/j.ejca.2012.07.004
  19. Zainal AO, Nor SIT (2011). National Cancer Registry Report 2007. Ministry of Health, Malaysia.
  20. Zhang L, Chen QY, Liu H, Tang LQ, Mai HQ (2013). Emerging treatment options for nasopharyngeal carcinoma. Drug Des Devel Ther, 7, 37-52.
  21. Zhang L, Zhao C, Peng PJ, et al (2005). Phase III study comparing standard radiotherapy with or without weekly oxaliplatin in treatment of locoregionally advanced nasopharyngeal carcinoma: preliminary results. J Clin Oncol, 23, 8461-8. https://doi.org/10.1200/JCO.2004.00.3863

Cited by

  1. A Retrospective Study of Clinicoepidemiological Aspects of Nasopharyngeal Cancer at NCI-Cairo (2000-2010) vol.06, pp.11, 2015, https://doi.org/10.4236/jct.2015.611105
  2. RNF8 plays an important role in the radioresistance of human nasopharyngeal cancer cells in vitro vol.34, pp.1, 2015, https://doi.org/10.3892/or.2015.3958
  3. Prognostic factors of nasopharyngeal carcinoma patients in a tertiary referral hospital: a retrospective cohort study vol.10, pp.1, 2017, https://doi.org/10.1186/s13104-017-2990-1